{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.78","upperLimit":"8.84","value":"6.93"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"5.75","value":"4.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"DOR was defined as the time from the date of the first response (CR or PR), until the date of PD or death from any cause, whichever occurred first. DOR for participants who have not progressed or died at the time of analysis are censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also have demonstrated an absolute increase of at least 5 mm. DOR was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.","id":"OG000","title":"Mirvetuximab Soravtansine"},{"description":"Participants randomized to IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.","id":"OG001","title":"Investigator's Choice (IC) Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo). Here, \"Overall number of participants analyzed\" is the number of evaluable participants for this outcome measure who had CR or PR.","reportingStatus":"POSTED","timeFrame":"Up to approximately 34 months","title":"Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}